SEC Comment Letter for ACHIEVE LIFE SCIENCES, INC. (ACHV) (CIK 0000949858) (ACHV) — Apr 15, 2013

ACHIEVE LIFE SCIENCES, INC. (ACHV) (CIK 0000949858)
Date: April 15, 2013 · CIK: 0000949858 · Accession: 0000000000-13-020171

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

April 3, 2013

Author

/s/ Daniel Greenspan for

Form

UPLOAD

Company

ACHIEVE LIFE SCIENCES, INC. (ACHV) (CIK 0000949858)

Letter

April 15 , 2013 Via E -mail Mr. Scott Cormack President and Chief Executive Officer OncoGenex Pharmaceuticals, Inc. 1522 – 217th Place S.E., Suite 100 Bothell, Washington 98021

Re: OncoGenex Pharmaceuticals, Inc. Preliminary Proxy Statement on Schedule 14A Filed on April 3, 2013 File No. 033-80623

Dear Mr. Cormack:

We have comple ted our review of your filing . We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal secur ities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules requ ire.

Sincerely,
/s/ Daniel Greenspan for

Show Raw Text

April 15 , 2013

Via E -mail
Mr. Scott Cormack
President and Chief Executive Officer
OncoGenex Pharmaceuticals, Inc.
1522 – 217th Place S.E., Suite 100
Bothell, Washington 98021

Re: OncoGenex Pharmaceuticals, Inc.
  Preliminary Proxy Statement on Schedule 14A
Filed on April 3, 2013
  File No.  033-80623

Dear Mr. Cormack:

We have comple ted our review of your filing .  We remind you that our comments or
changes to disclosure in response  to our comments do not foreclose the Commission from taking
any action with respect  to the company or the filing  and the company may not assert staff
comments as a defense in any proceeding initiated by the Commission or any person under the
federal secur ities laws of the United States.  We urge all persons who are responsible for the
accuracy and adequacy of the disclosure in the filing  to be certain that the filing includes  the
information the Securities Exchange Act of 1934 and all applicable rules requ ire.

Sincerely,

 /s/ Daniel  Greenspan for

Jeffrey P. Riedler
Assistant Director

SecProbe.io